In fact, genomic analyses have shown that many cancers, especially breast cancer and non-small cell lung cancer (NSCLC), exhibit amplification and upregulated expression of SGOC metabolic enzymes, such as PHGDH and SHMT2 [61, 62]. This evidence concerns the gene PHGDH and breast carcinoma.